Hepatitis Drug Market Sales Revenue Clinical Trials Pipeline Report 2023

“Global Hepatitis Drug Market and Clinical Trials Insight 2023” report gives comprehensive insight on various clinical and non-clinical advancements in the global Hepatitis drug market. Currently, there are 321 Hepatitis drugs in clinical pipeline and 110 Hepatitis drugs are commercially available in the market. Hepatitis drug clinical trials landscape is dominated by Hepatitis C drug with 145 drugs in various phases of development and 25 drugs commercially available in the market. The overall Hepatitis drug revenues are expected to surpass US$ 70 Billion by 2023 with major share accounted by Hepatitis C drugs.

Download Report:

https://www.kuickresearch.com/report-global-hepatitis-drug-market-and-clinical-trials-insight-2023.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Global Hepatitis Drug Market and Clinical Trials Insight 2023"

1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease

2. Global Prevalence of Hepatitis Infection

3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase Inhibitors Therapy
3.4 Toll like Receptor Agonists Therapy

4. Global Hepatitis Drug Market Analysis
4.1 Introduction
4.2 Global Hepatitis Drug Market Insight

5. Global Hepatitis Drug Market Dynamics
5.1 Favorable Market Parameters
5.2 Market Challenges

6. Future Perspective of Hepatitis Therapeutics

7. Global Hepatitis Drug Clinical Pipeline Overview
7.1 Hepatitis A
7.2 Hepatitis B
7.3 Hepatitis C
7.4 Hepatitis D
7.5 Hepatitis E

8. Hepatitis A Drug Clinical Trials Insight by Phase and Drug Class (5 Drugs)
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-III

9. Marketed Hepatitis A Drug Clinical Insight by Drug Class (12 Drugs)

10. Hepatitis B Drug Clinical Trials Insight by Phase and Drug Class (134 Drugs)
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-II/III
10.9 Phase-III
10.10 Preregistration
10.11 Registered

11. Marketed Hepatitis B Drug Clinical Insight by Drug Class (46 Drugs)

12. Hepatitis C Drug Clinical Trials Insight by Phase and Drug Class (145 Drugs)
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
12.11 Registered

13. Marketed Hepatitis C Drug Clinical Insight by Drug Class (25 Drugs)
13.1 ZEPATIER
13.2 Harvoni
13.3 Victrelis
13.4 Copegus
13.5 Sovaldi
13.6 Vanihep
13.7 Incivek
13.8 Olysio
13.9 VIEKIRA
13.10 Infergen
13.11 Viekirax
13.12 Epclusa
13.13 Ximency
13.14 Daclatasvir + Asunaprevir Combination
13.15 Peginterferon Alfa-2b (Y-shaped pegylation)
13.16 Golotimod
13.17 Algeron
13.18 Pegetron
13.19 Rebetron
13.20 IBAVYR
13.21 Reiferon Retard
13.22 Reiferon - Interferon Alpha-2a Biosimilar
13.23 Interferon Alpha-2a
13.24 Glycyron Tablets
13.25 Daklinza

14. Hepatitis D Drug Clinical Trials Insight by Phase and Drug Class (4 Drugs)
14.1 Research
14.2 Preclinical
14.3 Phase-II

15. Hepatitis E Drug Clinical Trials Insight by Phase and Drug Class ( 2 Drugs)
15.1 Preclinical
15.2 Phase-I

16. Marketed Hepatitis E Drug Clinical Insight by Drug Class (1 Drug)

17. Multiple Hepatitis Drug Clinical Trials Insight by Phase and Drug Class (31 Drugs)
17.1 Unknown
17.2 Research
17.3 Preclinical
17.4 Clinical
17.5 Phase-I
17.6 Phase-I/II
17.7 Phase-II
17.8 Preregistration

18. Marketed Multiple Hepatitis Drug Clinical Insight by Drug Class (26 Drugs)

19. Competitive Landscape
19.1 Arbutus Biopharma
19.2 Biostar Pharmaceuticals
19.3 Bristol-Myers Squibb
19.4 GlaxoSmithKline
19.5 Gilead Sciences
19.6 Enanta
19.7 Achillion
19.8 Presidio
19.9 Benitec Biopharma
19.10 Janssen Pharmaceuticals
19.11 AbbVie
19.12 Merck
19.13 Novira Therapeutics
19.14 Contravir
19.15 VBI Vaccines

Figure 1-1: Pathogenesis of Liver by the Exposure of Different Factors
Figure 1-2: Historical Development of Hepatitis Drug Treatment
Figure 1-3: Factors which are Responsible for Hepatitis Disease Development
Figure 2-1: Global - Incidence and Mortality Cases of Hepatitis B Infection (Million), 2015
Figure 2-2: Global - Incidence and Mortality Cases of Hepatitis C Infection (Million), 2015
Figure 3-1: Interferon Alpha - Mechanism of Action for Treating Liver Disease
Figure 3-2: Toll like Receptors and Activation of Antiviral Innate and Adaptive Immune Responses in Hepatitis Virus Infection
Figure 4-1: Global- Hepatitis B and C as Cause for Liver Cancer (%)
Figure 4-2: Global - Hepatitis Drug Market (US$ Billion), 2016 - 2023
Figure 4-3: Global- Hepatitis B Drug Market (US$ Billion), 2016-2023
Figure 4-4: Global - Hepatitis C Drug Market (US$ Billion), 2016-2023
Figure 5-1: Favorable Parameters to Hepatitis Drug Treatment Market Growth
Figure 5-2: Challenges to Hepatitis Therapeutic Market Growth
Figure 6-1: Future Landscape of Hepatitis Infection Treatment Research
Figure 7-1: Global - Hepatitis A Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-2: Global - Hepatitis A Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-3: Global - Hepatitis B Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-4: Global - Hepatitis B Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-5: Global Hepatitis C Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-6: Global Hepatitis C Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-7: Global - Hepatitis D Drug Clinical Pipeline By (%), 2017 till 2023
Figure 7-8: Global - Hepatitis D Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-9: Global - Hepatitis E Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-10: Global - Hepatitis E Drug Clinical Pipeline by Phase (Number), 2017 till 2023


Table 3-1: Protease Inhibitors in Development for Hepatitis Disease Treatment
Table 3-2: Toll like Receptor Affecting Immunopathogenesis of Hepatitis Virus Infection

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.